6,262 Axsome Therapeutics, Inc. $AXSM Shares Bought by Profund Advisors LLC

Profund Advisors LLC grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 608.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 7,291 shares of the company’s stock after acquiring an additional 6,262 shares during the period. Profund Advisors LLC’s holdings in Axsome Therapeutics were worth $1,344,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Axsome Therapeutics during the 2nd quarter worth $759,695,000. ABS Investment Management LLC bought a new position in shares of Axsome Therapeutics during the second quarter worth approximately $171,339,000. Bank of America Corp DE bought a new position in shares of Axsome Therapeutics during the second quarter worth approximately $110,756,000. First Trust Advisors LP raised its position in shares of Axsome Therapeutics by 1,230.2% in the first quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after buying an additional 534,066 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $55,171,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AXSM. Royal Bank Of Canada reissued an “outperform” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 14th. Needham & Company LLC lifted their price objective on Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. UBS Group reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Monday, August 24th. Piper Sandler reduced their target price on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. Finally, Mizuho raised their price target on Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $274.68.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Axsome posted third-quarter revenue of $259.7 million, up 51.9% year over year and ahead of the approximately $249.2 million consensus estimate. Its loss narrowed to $0.25 per share, substantially better than the expected $0.63–$0.69 loss and the $0.94 loss in the prior-year quarter. Axsome Therapeutics Third-Quarter Financial Results
• Positive Sentiment: Sales increased across Axsome’s key commercial brands, supporting the company’s improving revenue base. Management also highlighted pipeline milestones expected in 2027, which could provide additional long-term growth opportunities. Axsome Q3 Sales and Pipeline Milestones
• Neutral Sentiment: The earnings beat was partly offset by continued negative profitability metrics, including a negative net margin and return on equity. Investors may therefore view the results as evidence of progress, but not yet as proof of sustainable earnings power. Axsome Q3 Key Metrics
• Negative Sentiment: AUVELITY’s ADA launch is progressing more slowly than hoped. Recent incremental growth appears to be driven more by depression prescriptions among patients under 65 than by ADA prescriptions, raising concerns about the size and pace of the new indication’s commercial opportunity. Axsome Therapeutics Sentiment Meets Reality After Q3
• Negative Sentiment: Analysts questioned the durability of the revenue beat because one-time items and improved gross-to-net adjustments contributed to reported sales, rather than solely stronger prescription volume. Piper Sandler also trimmed its price target to $235 from $238, reflecting more cautious expectations. Piper Sandler Lowers Axsome Price Target

Insiders Place Their Bets

In related news, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $213.95, for a total transaction of $997,007.00. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at $1,546,644.55. This represents a 39.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 59,664 shares of company stock worth $12,624,805 in the last ninety days. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $136.01 on Tuesday. Axsome Therapeutics, Inc. has a 12-month low of $123.00 and a 12-month high of $260.19. The business has a 50-day simple moving average of $183.33 and a two-hundred day simple moving average of $198.74. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.38. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The business had revenue of $259.69 million for the quarter, compared to the consensus estimate of $249.19 million. During the same period last year, the company earned ($0.94) EPS. The firm’s revenue was up 51.9% compared to the same quarter last year. As a group, analysts predict that Axsome Therapeutics, Inc. will post -3.04 EPS for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.